tiprankstipranks
Trending News
More News >

Tryptamine Therapeutics Announces Director Resignation

Story Highlights
Tryptamine Therapeutics Announces Director Resignation

Confident Investing Starts Here:

Tryptamine Therapeutics ( (AU:TYP) ) has issued an update.

Tryptamine Therapeutics Limited announced the resignation of Mark Davies as a director, effective May 12, 2025. This change in leadership is accompanied by a disclosure of Davies’ interests in the company’s securities, including various unlisted director options and ordinary fully paid shares. The departure of a director may impact the company’s strategic direction and stakeholder confidence, particularly given Davies’ significant holdings and involvement with the company.

More about Tryptamine Therapeutics

Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development of innovative therapeutic solutions. The company is involved in the research and production of treatments that aim to address various health conditions, with a particular emphasis on advancing mental health therapies.

Average Trading Volume: 1,751,616

Technical Sentiment Signal: Buy

Current Market Cap: A$50.36M

See more data about TYP stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App